Therapy of chronic hepatitis B: current challenges and opportunities (Q34996613)

5 August 2017

1 reference

title

Therapy of chronic hepatitis B: current challenges and opportunities (English)

1 reference

5 August 2017

1 reference

1 reference

Liaw YF

1

0 references

language of work or name

1 reference

1 November 2002

1 reference

Journal of Viral Hepatitis

5 August 2017

1 reference

5 August 2017

9

1 reference

5 August 2017

393-399

1 reference

5 August 2017

6

1 reference

Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B

5 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Varied assembly and RNA editing efficiencies between genotypes I and II hepatitis D virus and their implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Chronic hepatitis B guidelines: east versus west.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Mechanisms of action of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Reinfection rate following effective therapy against Helicobacter pylori infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Viral dynamics in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Nucleoside analogues in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Drug treatment of pediatric chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Clinical trial of lamivudine in children with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Lamivudine as initial treatment for chronic hepatitis B in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

Lamivudine resistance inimmunocompetent chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00388.X

10.1046/J.1365-2893.2002.00388.X

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12431200